4.4 Article

Incidence and mortality of super-refractory status epilepticus in adults

期刊

EPILEPSY & BEHAVIOR
卷 49, 期 -, 页码 131-134

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yebeh.2015.04.065

关键词

Mortality; Status epilepticus; Superrefractory; ICU; Incidence

资金

  1. Kuopio University Hospital VTR
  2. Finnish Epilepsy Research Foundation

向作者/读者索取更多资源

Objectives:Super-refractory status epilepticus (SRSE) is defined as status epilepticus (SE) that continues or recurs 24 h or more after the onset of anesthetic therapy. We defined the incidence and outcome of SRSE in adults in Finland. Methods: We analyzed retrospectively the Finnish Intensive Care Consortium database in order to identify adult patients with SRSE treated in ICUs in Finland during a three-year period (2010-2012). The database consists of admissions to all 20 Finnish hospitals treating refractory SE (RSE) with general anesthesia in the intensive care unit (ICU). We included consecutive adult (16 years or older) patients with RSE and identified those who had SRSE. Patients with postanoxic etiologies were excluded. Results: All five university hospitals and 10/15 of the central hospitals participated. The adult referral population of the study hospitals is 3.9 million, representing 91% of the total adult population of Finland. We identified 395 patients with ICU-treated RSE, 87 (22%) of whom were classified as having SRSE. This corresponds to an annual incidence of SRSE of 0.7/100,000 (95% confidence interval [CI]: 0.6-0.9). The one-year mortality rates were 36% (95% Cl: 26-46%) for patients with SRSE and 22% (95% Cl: 17-27%) for patients with RSE. Mortality was highest (63%) in patients with SRSE aged over 75 years. Conclusions: Approximately 20% of patients with RSE treated in Finnish ICUs progressed to having SRSE. The incidence of SRSE, 0.7/100,000, is about 5-10% of the incidence of SE. The mortality of patients with SRSE, 36%, was comparable to earlier studies and twofold higher than the mortality of patients with RSE. (C) 2015 Elsevier Inc. All rights reserved,

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据